Efficacy and safety of incretin based therapies: clinical trial data.
about
Alogliptin as an initial therapy in patients with newly diagnosed, drug naïve type 2 diabetes: a randomized, control trialEfficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial with an open-label, long-term extension studyGLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?Pramlintide and the treatment of diabetes: a review of the data since its introduction.Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular dataGlycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapiesReal-world clinical and economic outcomes of liraglutide versus sitagliptin in patients with type 2 diabetes mellitus in the United States.Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review.Comparative Assessment of Lixisenatide, Exenatide, and Liraglutide Pen Devices: A Pilot User-Based Study.Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus.LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial.Therapy in the early stage: incretins.Comparative efficiency and safety of pharmacological approaches to the management of obesity.Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in ArgentinaManagement of type 2 diabetes mellitus in the elderly: role of the pharmacist in a multidisciplinary health care team.The future of incretin-based therapy: novel avenues--novel targets.Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings.The cardiovascular safety of incretin-based therapies: a review of the evidence.Insulin degludec/liraglutide: innovation-driven combination for advancement in diabetes therapy.Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.Contemporary management of patients with Type 2 diabetes.The role of efferent cholinergic transmission for the insulinotropic and glucagonostatic effects of GLP-1.
P2860
Q28257600-C57E275C-D3A0-4ED6-A3DC-C74E1002A999Q33587818-3564FD39-474C-4CBF-A8E9-C070A3C4FFFCQ33734024-A2A2DA02-BA22-42E3-A13A-9B39D75DF16CQ33896433-A8C034B7-8214-4501-817C-ADAA6FBF5D56Q34128612-154F21EE-1D16-40CC-B9A0-67940747EF0BQ34265490-CB26397E-E221-4B07-ABAC-34EB59E679B1Q34627077-01262FBA-04AC-4962-A6CE-677588FDE61FQ34726493-8AD30149-61F6-46E3-9BAA-7EB443271813Q35003229-9792FAF9-A107-44BC-9C6E-A1D479E4496FQ35679062-F0E710E5-36BD-4663-8415-3E291F6E129CQ36043971-D4D49AD8-4933-4913-AC80-64EC5E66C314Q36105649-6F9AC088-3B02-46D4-B8ED-5FE90E54530DQ36783865-9BB0CD23-41DA-425C-9BD8-420F09AF4FB0Q36783891-93E6DF43-DA8E-4F8E-86BF-4946D0B293CDQ36835225-CDB34185-2EC6-4E58-ACD1-FC8FC42570E8Q37886705-6B1E9598-90D9-48E6-B1D9-9B3A2548B1D8Q37913528-36EAF009-9375-4FFF-96BE-6FF2328E242DQ38005223-CEEA469C-CCA8-4F97-810A-3E3568E1C9B8Q38014516-FA6E5B94-43E1-44F9-89FE-DDBF1ED2E23AQ38134902-2A95AF56-DC89-49C9-A6FC-280E81501031Q38202156-8C9CBF38-07C2-4810-8715-4173062D7C29Q38751579-EB2F88E6-C5F7-4680-A5D3-D58C16508F46Q43042719-281E4E97-773B-4402-BDA7-53204E94A326Q53443415-3FC4407D-949D-4F75-B50A-EE461D6827CC
P2860
Efficacy and safety of incretin based therapies: clinical trial data.
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Efficacy and safety of incretin based therapies: clinical trial data.
@ast
Efficacy and safety of incretin based therapies: clinical trial data.
@en
type
label
Efficacy and safety of incretin based therapies: clinical trial data.
@ast
Efficacy and safety of incretin based therapies: clinical trial data.
@en
prefLabel
Efficacy and safety of incretin based therapies: clinical trial data.
@ast
Efficacy and safety of incretin based therapies: clinical trial data.
@en
P356
P1476
Efficacy and safety of incretin based therapies: clinical trial data.
@en
P2093
John White
P304
P356
10.1331/JAPHA.2009.09079
P478
49 Suppl 1
P577
2009-09-01T00:00:00Z